-
June 15, 2021
EISAI TO DIVEST RIGHTS FOR ZONEGRAN® IN EUROPE AND OTHER REGIONS TO ADVANZ PHARMA
-
June 9, 2021
-
June 9, 2021
EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 35th ANNUAL SLEEP MEETING (SLEEP2021)
-
June 8, 2021
Biogen and Eisai launch initiatives to help patients with Alzheimer’s disease access ADUHELM™
-
June 8, 2021
-
June 10, 2021
-
May 20, 2021
IR “Notice of Convocation of the 109th Ordinary General Meeting of Shareholders”
-
May 13, 2021
IR “Annual Financial Results Briefing for the Fiscal Year Ended March 31, 2021 [Material, Webcast]”
-
May 12, 2021
IR “Annual Financial Report for the Fiscal Year Ended March 31, 2021”
-
April 5, 2021
-
April 19, 2021
Eisai formulates the action plan “Diversity & Inclusion 2021”
-
December 10, 2020
Notice of Emergence of Employees Infected with the Novel Coronavirus at the Bogor Plant in Indonesia
-
December 3, 2020
EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT FIFTH ANNUAL WELFARE INDEX PMI* IN ITALY
-
October 28, 2020
-
August 4, 2020
Notice of Emergence of Employees Infected with the Novel Coronavirus at Eisai’s Vizag Plant in India
-
Annual Financial Results for the Fiscal Year Ended March 31, 2021
-
Our Response to the Novel Coronavirus Infection
-
Florence Nightingale Virtual Gallery
-
#ThisIsMBC Elements Campaign Showcases Powerful Portraits of Patients Living with Metastatic Breast Cancer and Their Caregivers Sharing Their Journeys to Inspire Others
Eisai's hhc Philosophy
Sustainability
28 countries 2.02 billion tablets
Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of May 2021)
Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries
